Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Serwetnyk

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Acta Pharmaceutica Sinica. B|July 5, 2021
The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibitionMichael A Serwetnyk, Brian S J Blagg
Chemical Biology & Drug Design|April 12, 2026
Attempts to Achieve Targeted Covalent Inhibition of Hsp90βTerin D'Amico, Tyelor S Reynolds, Michael A Serwetnyk, et al.
Chemmedchem|November 18, 2025
Hsp90β-Selective Inhibitors: Probing the Solvent-Accessible FrontierTerin D'Amico, Michael A Serwetnyk, Xiaozheng Dou, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast CancerMichael A Serwetnyk, Vincent M Crowley, Christopher M Brackett, et al.
European Journal of Medicinal Chemistry|July 9, 2025
Optimization of an Hsp90β-selective inhibitor via exploration of the Hsp90 N-terminal ATP-binding pocketMichael A Serwetnyk, Taddäus Strunden, Ian Mersich, et al.
Iscience|November 29, 2023
Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancerNada H Eisa, Vincent M Crowley, Asif Elahi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Acta Pharmaceutica Sinica. B|July 5, 2021
The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibitionMichael A Serwetnyk, Brian S J Blagg
Chemical Biology & Drug Design|April 12, 2026
Attempts to Achieve Targeted Covalent Inhibition of Hsp90βTerin D'Amico, Tyelor S Reynolds, Michael A Serwetnyk, et al.
Chemmedchem|November 18, 2025
Hsp90β-Selective Inhibitors: Probing the Solvent-Accessible FrontierTerin D'Amico, Michael A Serwetnyk, Xiaozheng Dou, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast CancerMichael A Serwetnyk, Vincent M Crowley, Christopher M Brackett, et al.
European Journal of Medicinal Chemistry|July 9, 2025
Optimization of an Hsp90β-selective inhibitor via exploration of the Hsp90 N-terminal ATP-binding pocketMichael A Serwetnyk, Taddäus Strunden, Ian Mersich, et al.
Iscience|November 29, 2023
Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancerNada H Eisa, Vincent M Crowley, Asif Elahi, et al.
Pageof 1